DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for Tietz syndrome — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleTietz syndrome maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for tietz syndrome is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
melanocyte inducing transcription factor (MITF) — MITF is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet apo structuredrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 7D8S · 2.28 Å · ligand none (apo structure). Experimental structure, not a prediction.
What the evidence adds up to
Tietz syndrome is an autosomal dominant condition caused by mutations in the MITF gene. A 2000 study of the single reported family with the full syndrome found a missense mutation in the basic region of MITF. The syndrome is defined by congenital profound deafness and generalised hypopigmentation with complete penetrance, which distinguishes it from Waardenburg syndrome type 2, where depigmentation is patchy and hearing loss variable. A 1998 report described a mother and son with albinism and sensorineural deafness compatible with Tietz syndrome who carried an in-frame deletion in MITF identical to a mouse mi mutant allele. That paper noted that MITF mutations account for 20% of Waardenburg syndrome type II.
A 2016 study of two unrelated families with MITF mutations reported that all patients except one had bilateral reduced ocular anteroposterior axial length and high hyperopic refractive error, a feature called posterior microphthalmos that had not previously been described in Tietz or Waardenburg syndrome type 2A. In the first family, a heterozygous c.648A>C mutation in exon 8 was found; in the second, an isolated patient, a de novo heterozygous c.1183_1184insG truncating mutation in exon 10 was identified. The authors suggested posterior microphthalmos may be part of the clinical spectrum.
No treatment or intervention is discussed in any of these abstracts. The evidence is limited to fewer than five families worldwide, and no clinical trials, drug repurposing studies, or therapeutic strategies have been reported. What is missing is any systematic patient registry, natural history data beyond ocular measurements, and any funded effort to develop or test a treatment for the deafness or hypopigmentation.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Journal of Medical Genetics · 2000 · 152 citations · open access
Tietz syndrome (hypopigmentation/deafness) caused by mutation of<i>MITF</i>: Figure 1
AbstractPatients with Tietz syndrome have congenital profound deafness and generalised hypopigmentation, inherited in a fully penetrant autosomal dominant fashion. The pigmentary features and complete penetrance make this syndrome distinct among syndromes with pigmentary anomalies and deafness, which characteristically have patchy depigmentation and variable penetrance. Only one family has been reported with the exact features described in the original report of this syndrome. This family was reascertained and a missense mutation was found in the basic region of the MITF gene in family members with Tietz syndrome. Mutations in other regions of this gene have been found to produce Waardenburg syndrome type 2 (WS2), which also includes pigmentary changes and hearing loss, but in contrast to Tietz syndrome, depigmentation is patchy and hearing loss is variable in WS2.
Mutation of the MITF gene in albinism-deafness syndrome (Tietz syndrome)
AbstractA mother and her son with albinism and sensorineural deafness compatible with Tietz syndrome (MIM 103500) are reported. An in-frame deletion of the MITF gene that is identical at the molecular level to the mouse mi mutant allele has been found in this family. MITF gene mutations account for 20% of Waardenburg syndrome (WS) type II. These data, together with the wide spectrum of mutant alleles reported in mi mice (which have pigmentary disorders), suggest that MITF could be regarded as a candidate gene in various pigmentation disorders in man.
Laryngo-Rhino-Otologie · 2018 · 0 citations · open access
Case report: Congenital profound deafness and Cochlea Implantation in Tietz syndrome (hypopigmentation/deafness)
AbstractThe Tietz syndrome is a rare, autosomal dominant disease. Its exact prevalence is unknown. So far, only a few affected families have been identified. It is manifested by congenital high-grade inner ear hearing loss, fair skin and light colored hair. It is caused by mutations in the MITF gene, which either leads to the deletion or to the modification of a protein-forming block. It is believed that the Tietz syndrome is a severe form of the Waardenburg syndrome, which is also caused by MITF gene mutations.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
